drugset / Trial / NCT03752177
A Study of LY3415244 in Participants With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the safety of LY3415244, a PD-L1/TIM-3 bispecific antibody, administered as monotherapy to participants with advanced solid tumors.
Timeline
- Start
- 2018-11-22
- Primary completion
- 2019-10-09
- Completion
- 2019-10-09
Outcome
Outcome not reported
Stopped: “The study was terminated during dose escalation after a determination was made that the risk:benefit ratio no longer favored continued evaluation.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY3415244 | Unknown | 3 mg | Intravenous |
| Subject | LY3415244 | Unknown | 10 mg | Intravenous |
| Subject | LY3415244 | Unknown | 30 mg | Intravenous |
| Subject | LY3415244 | Unknown | 70 mg | Intravenous |